WHAT IS SIMPONI ARIA^® (golimumab)?

SIMPONI ARIA^® has:

• 10+ years of experience with an estimated 64,000 patients treated in the United States across all approved indications^²
• Improvement in signs and symptoms in adult patients with PsA and RA (ACR20 response at Week 14) and AS (ASAS20 response at Week 16)^¹

  The first and only anti-TNFα biologic with improvement in both the mental and physical components of SF-36 across PsA, RA, and AS in adult patients, and improvement in fatigue as measured by FACIT-F across PsA and RA in adult patients

• Demonstrated safety profile^¹
• An infusion experience you can control^¹An efficient 30-minute infusion given at Weeks 0 and 4, then every 8 weeks thereafter—as few as 6 times a year_{"Efficient" is defined as the total amount of time required to infuse.}Weight-based dosing (2 mg/kg) for adult patientsNo reconstitution required
• Support for your patients and your practice Find out more about Access and AffordabilityJanssen CarePath Contract Purchase Program